Soliqua 100/33 33 ug/mL

Soliqua 100/33 33 ug/mL is a combination of insulin glargine and lixisenatide, designed for subcutaneous administration. This medication is used to manage blood sugar levels in adults with type 2 diabetes. It combines the effects of a long-acting insulin and a GLP-1 receptor agonist for comprehensive diabetes care.

Soliqua 100/33 33 ug/mL is primarily used for the management of type 2 diabetes in adults. It works by combining insulin glargine, which helps control blood sugar levels over a prolonged period, and lixisenatide, a GLP-1 receptor agonist that enhances insulin secretion and reduces appetite. This dual-action approach aims to improve glycemic control and support overall diabetes management.

Common effects of Soliqua 100/33 33 ug/mL may include hypoglycemia, nausea, vomiting, and injection site reactions. Some individuals might experience gastrointestinal discomfort or changes in appetite. It is important to monitor blood sugar levels regularly while using this medication to ensure optimal results and minimize potential side effects.

Soliqua 100/33 33 ug/mL should be handled with care, ensuring proper storage and administration techniques. It is crucial to follow the prescribed dosage and administration guidelines provided by a healthcare professional. Always check the solution for particles or discoloration before use. Individuals with a history of severe hypoglycemia or pancreatic issues should discuss their medical history with their healthcare provider before starting this medication.

Soliqua 100/33 33 ug/mL may interact with other medications, including oral hypoglycemic agents, corticosteroids, and certain antidepressants. Alcohol consumption can also affect blood sugar levels and should be monitored closely. It is important to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.